Analysts Anticipate KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Will Post Earnings of -$1.01 Per Share

Equities analysts expect KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Rating) to report earnings per share of ($1.01) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for KalVista Pharmaceuticals’ earnings, with estimates ranging from ($1.19) to ($0.81). KalVista Pharmaceuticals posted earnings per share of ($0.65) during the same quarter last […]

Related Keywords

Canada ,Thomas Andrew Crockett ,Securities Exchange Commission ,Life Insurance Co ,Zacks Investment Research ,Nasdaq ,Capital Partners ,Kalvista Pharmaceuticals Company Profile Get Rating ,Needham Company ,Kalvista Pharmaceuticals Inc ,Jpmorgan Chase Co ,Kalvista Pharmaceuticals ,Royal Bank ,Get Rating ,Kalvista Pharmaceutical ,Vista Pharmaceuticals ,Investment Research ,Roth Capital ,Andrew Crockett ,Exchange Commission ,Vista Pharmaceuticals Company Profile ,Nasdaq Kalv ,Kalv ,Medical ,Ratings ,Consensus ,